StreetInsider.com News Articles

Scienture expands naloxone spray access through GPO deals

Wed, 11 Mar 2026 08:06:30 -0400

Scienture Holdings Inc. (NASDAQ: SCNX) announced it has secured group purchasing organization agreements for its REZENOPY naloxone nasal spray, providing access to more than 5,000 healthcare institutions across the United States.

The agreements cover hospitals, clinics, nursing homes, emergency medical services providers and rehabilitation centers. The company stated the deals represent potential penetration into approximately 60% of the U.S. institutional market for naloxone products.

REZENOPY is a 10 mg naloxone hydrochloride nasal spray approved by the FDA for emergency treatment of opioid overdoses. The company describes it as the highest-dose naloxone nasal spray approved by the FDA.

"These GPO agreements represent a significant

SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions

Wed, 11 Mar 2026 08:05:00 -0400

Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, while expanding reach across EMS providers and rehabilitation centers

U.S. naloxone market totals $141M with 9.4 million prescription units annually, represents significant commercial opportunity for REZENOPY^™

COMMACK, NY, March 11, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it

SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions

Wed, 11 Mar 2026 08:05:00 -0400

Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, while expanding reach across EMS providers and rehabilitation centers

U.S. naloxone market totals $141M with 9.4 million prescription units annually, represents significant commercial opportunity for REZENOPY^™

Maxim Group Starts Scienture Holdings (SCNX) at Buy

Tue, 24 Feb 2026 07:37:47 -0400

Maxim Group analyst Naz Rahman initiates coverage on Scienture Holdings (NASDAQ: SCNX) with a Buy rating and a price target of $1.50.

For an analyst ratings summary and ratings history on Scienture Holdings click here. For more ratings news on Scienture Holdings click here.

Shares of Scienture Holdings closed at $0.37 yesterday.

SCIENTURE expands access for ARBLI oral losartan suspension

Tue, 03 Feb 2026 08:06:39 -0400

SCIENTURE Holdings Inc (NASDAQ: SCNX) announced commercial progress for ARBLI, its FDA-approved ready-to-use oral suspension of losartan potassium, and confirmed plans to launch REZENOPY naloxone nasal spray in the second quarter of 2026.

The company secured multiple pharmacy benefit manager-led group purchasing organization rebate agreements and institutional GPO agreements, expanding access to more than 2,500 healthcare institutions. SCIENTURE achieved formulary inclusion with major national health plans, covering over 100 million lives, and established a collaboration with BlinkRx for patient access and fulfillment services.

"These milestones significantly expand the commercial opportunity for ARBLI and represent an important inflection point in its launch trajectory,"

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Tue, 03 Feb 2026 08:05:00 -0400

Company highlights accelerating access and revenue growth for ARBLI^™ and confirms REZENOPY^™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million

Outlines Q1 2026 outlook and reports significant balance sheet improvement last quarter

COMMACK, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a commercial

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Tue, 03 Feb 2026 08:05:00 -0400

Outlines Q1 2026 outlook and reports significant balance sheet improvement last quarter

SCIENTURE receives patent for REZENOPY naloxone nasal spray

Wed, 14 Jan 2026 08:06:40 -0400

Scienture Holdings Inc. (NASDAQ: SCNX) announced the U.S. Patent and Trademark Office issued U.S. Patent No. 12,514,854 B2 covering REZENOPY naloxone HCl nasal spray 10 mg, effective January 6, 2026, with an expiry date of February 5, 2041.

The patent was issued to Summit Biosciences Inc., a subsidiary of Kindeva Drug Delivery L.P. Scienture holds exclusive U.S. commercialization rights to REZENOPY through a definitive agreement with Summit entered in March 2025. Under the collaboration terms, Summit will manufacture and supply the product while Scienture will handle sales, marketing and distribution.

REZENOPY received FDA approval on April 19, 2024. The newly issued patent

SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment

Wed, 14 Jan 2026 08:05:00 -0400

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually

COMMACK, NY, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,514,854 B2, an Orange Book-listable patent covering REZENOPY^™(naloxone HCl) Nasal Spray 10 mg, effective January 6, 2026, with

SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment

Wed, 14 Jan 2026 08:05:00 -0400

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually

Scienture expects commercial launch of naloxone spray in Q2 2026

Mon, 22 Dec 2025 08:05:30 -0400

Scienture Holdings Inc. (NASDAQ: SCNX) announced an update on the commercial launch timeline for REZENOPY, a 10 mg naloxone nasal spray for opioid overdose treatment.

The company expects to load REZENOPY into wholesale channels during the first quarter of 2026, with commercial availability beginning in early second quarter 2026. Manufacturing efforts remain on track for product readiness in the first quarter of 2026, according to the company.

REZENOPY received FDA approval on April 19, 2024. Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, entered into an exclusive U.S. commercialization agreement with Summit Biosciences Inc. in March 2025 for the product.

The naloxone

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

Mon, 22 Dec 2025 08:05:00 -0400

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually

COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided an update on the commercial launch of REZENOPY^®.

As previously disclosed, Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. entered into a definitive agreement with Summit Biosciences Inc.

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

Mon, 22 Dec 2025 08:05:00 -0400

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually

As previously disclosed, Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. entered into a definitive agreement with Summit Biosciences Inc.

SCIENTURE partners with BlinkRx to expand access to Arbli oral suspension